Anti-KRTAP19-3 monoclonal antibody
Pre-made anti-KRTAP19-3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to KRTAP19-3/KRTAP19-3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP1062-Ab-1/ GM-Tg-hg-IP1062-Ab-2 | Anti-Human KRTAP19-3 monoclonal antibody | Human |
| GM-Tg-rg-IP1062-Ab-1/ GM-Tg-rg-IP1062-Ab-2 | Anti-Rat KRTAP19-3 monoclonal antibody | Rat |
| GM-Tg-mg-IP1062-Ab-1/ GM-Tg-mg-IP1062-Ab-2 | Anti-Mouse KRTAP19-3 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP1062-Ab-1/ GM-Tg-cynog-IP1062-Ab-2 | Anti-Cynomolgus/ Rhesus macaque KRTAP19-3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP1062-Ab-1/ GM-Tg-felg-IP1062-Ab-2 | Anti-Feline KRTAP19-3 monoclonal antibody | Feline |
| GM-Tg-cang-IP1062-Ab-1/ GM-Tg-cang-IP1062-Ab-2 | Anti-Canine KRTAP19-3 monoclonal antibody | Canine |
| GM-Tg-bovg-IP1062-Ab-1/ GM-Tg-bovg-IP1062-Ab-2 | Anti-Bovine KRTAP19-3 monoclonal antibody | Bovine |
| GM-Tg-equg-IP1062-Ab-1/ GM-Tg-equg-IP1062-Ab-2 | Anti-Equine KRTAP19-3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP1062-Ab-1/ GM-Tg-hg-IP1062-Ab-2; GM-Tg-rg-IP1062-Ab-1/ GM-Tg-rg-IP1062-Ab-2; GM-Tg-mg-IP1062-Ab-1/ GM-Tg-mg-IP1062-Ab-2; GM-Tg-cynog-IP1062-Ab-1/ GM-Tg-cynog-IP1062-Ab-2; GM-Tg-felg-IP1062-Ab-1/ GM-Tg-felg-IP1062-Ab-2; GM-Tg-cang-IP1062-Ab-1/ GM-Tg-cang-IP1062-Ab-2; GM-Tg-bovg-IP1062-Ab-1/ GM-Tg-bovg-IP1062-Ab-2; GM-Tg-equg-IP1062-Ab-1/ GM-Tg-equg-IP1062-Ab-2 |
| Products Name | Anti-KRTAP19-3 monoclonal antibody |
| Format | mab |
| Target Name | KRTAP19-3 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-KRTAP19-3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP1062-Ag-1 | Recombinant multi-species KR193/ KRTAP19-3/ GTRHP protein |
Target information
| Target ID | GM-IP1062 |
| Target Name | KRTAP19-3 |
| Gene ID | 337970 |
| Gene Symbol and Synonyms | GTRHP,KAP19.3,KRTAP19-3 |
| Uniprot Accession | Q7Z4W3 |
| Uniprot Entry Name | KR193_HUMAN |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000244025 |
| Target Classification | N/A |
The target: KRTAP19-3, gene name: KRTAP19-3, also named as GTRHP, KAP19.3. Predicted to be located in cytosol. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

